Headquartered in New York City, Pfizer jumped past No- vartis to reclaim its spot as the largest pharmaceutical company in the world by revenue. The company reported
an 8% growth to $52.8 billion for 2016 as compared to $48.9 billion in 2015. Pfizer’s portfolio includes medicines, vaccines, and
consumer healthcare products separated into two businesses: Innovative Health and Essential Health.
The Innovative Health segment includes the global innovative
pharmaceuticals segment and the global vaccines, oncology, and
consumer healthcare segment and accounts for more than half of
the company’s total revenues. The revenue contribution from the
segment rose to 55% of total revenues for 2016. The Innovative
Health revenues increased 11% to $29.2 billion in 2016 primarily due to an increase in sales of Lyrica, Ibrance, Eliquis, Xeljanz,
Xtandi, and the strong performance of new products.
Pfizer Essential Health, formerly known as the Global Established Pharma segment, is focused on non-viral anti-infectives, biosimilars and sterile injectable medicines. The Essential
Health business also includes legacy Hospira products. In September 2015, Pfizer acquired Hospira to create a leading provider of global sterile injectables that now encompasses one of the
broadest and most diverse portfolios of sterile injectable medicines in the industry. The Essential Health segment revenue’s
rose 11% to $23.6 billion in 2016, driven by increased sales of
legacy Hospira products.
Many of Pfizer’s R&D pipeline’s new molecular entities are aimed
at a range of cancers, including kidney, breast, prostate, lung and
blood cancers, and include biologics, chemicals, immunotherapies, gene therapies and biosimilars.
In 2016, Pfizer achieved several regulatory milestones. Its
breakthrough oncology product Ibrance, which was approved
by the FDA in the U.S. in 2015 for the initial treatment of the
most common form of advanced breast cancer, received a new
U.S. indication for recurrent disease. Ibrance also was approved
in 2016 by the European Medicines Agency (EMA) for both initial
and recurrent disease. There are 77 ongoing or completed collaborative Ibrance studies with investigators, 43 of which are in
breast cancer and 34 in non-breast tumors including pancreatic
and head and neck cancers.
Xalkori, Pfizer’s treatment for non-small cell lung cancer, was
approved by the FDA for a certain type of lung cancer known as
Two therapies in development for cancer were accepted for
regulatory review in 2016. Inotuzumab for acute lymphoblastic leukemia is now in registration in the EU, and avelumab for
metastatic Merkel cell carcinoma is being reviewed in the U.S.
Together with its partner Merck KGaA, Pfizer is expanding its foothold in immuno-oncology where it currently has 30
avelumab clinical programs in the clinic and in 2016, launched
four “first-in-patient” studies and now has eleven immuno-oncology entries in the clinic. Pfizer is now well positioned to
capitalize on what many believe will be the future of cancer
treatment—immuno-oncology agents combined with more
DRIVING PROGRESS IN THE BIOSIMILARS MARKET
As the leading global biosimilars company, Pfizer currently has
three marketed biosimilars as part of its acquisition of Hospira—
Inflectra (infliximab-dyyb), Retacrit (epoetin zeta) and Nivestim
(filgrastim)—available to patients in several markets. Inflectra,
which is marketed under other brand names in some countries,
is approved in more than 70 countries. Pfizer’s robust biosimilars pipeline consists of eight distinct molecules in mid-to-late
stage development, and six in early-stage development. Three of
its late-stage pipeline products have reported positive top-line
data from Phase III studies, and full data results are anticipated
Over the past year, the company has also worked to advance
the U.S. biosimilars marketplace. In 2016, Pfizer launched Inflectra, a biosimilar for Remicade in the U.S. It marks the first
monoclonal antibody (mAb) biosimilar to be both approved and
launched in the U.S. It received FDA clearance in November 2016
and will treat difficult conditions including rheumatoid arthritis
(RA), Crohn’s disease, plaque psoriasis and ulcerative colitis (UC).
Pfizer’s 14 biosimilars in the pipeline are expected to compete in a global market that may grow to $17-20 billion over the
next five to 10 years. To offer support to patients and providers
in the U.S., Pfizer launched the Pfizer enCompass Program, a
comprehensive reimbursement and patient support program
Pfizer is also developing new therapies for improving the
quality of life of people who live with debilitating conditions
such as RA, lupus, psoriatic arthritis and inflammatory bowel disease (IBD), including UC. It’s expertise in Janus kinase inhibitors
(JAK), which interfere with the inflammation process in autoimmune diseases, is enabling it to advance several other potential
anti-inflammatory therapies beyond the marketed product Xeljanz. Pfizer anticipates initiating approximately six JAK studies
In addition, Pfizer has a rich history in vaccine research and
development, and in 2016 continued to improve and expand its
The headquarters of pharmaceutical giant Pfizer in Manhattan, New York. With $52.8
billion in 2016 revenue, Pfizer again is the top (bio)pharma company in the world.